Month: January 2023

Iron-Catalyzed Asymmetric Decarboxylative Azidation was written by Wang, Kaikai;Li, Yajun;Li, Xiaoyan;Li, Daliang;Bao, Hongli. And the article was included in Organic Letters in 2021.Reference of 83902-02-7 This article mentions the following:

The first iron-catalyzed asym. azidation of benzylic peresters has been reported with trimethylsilyl azide (TMSN₃) as the azido source. Hydrocarbon radicals that lack of strong interactions were capable to be enantioselectively azidated. The reaction features good functional group tolerance, high yields, and mild conditions. The chiral benzylic azides can further be used in click reaction, phosphoramidation, and reductive amination, which demonstrate the synthetic values of this reaction. In the experiment, the researchers used many compounds, for example, 2-(Bromomethyl)-1,3-dimethylbenzene (cas: 83902-02-7Reference of 83902-02-7).

2-(Bromomethyl)-1,3-dimethylbenzene (cas: 83902-02-7) belongs to organobromine compounds. Bromo compounds are employed in a variety of metal-catalyzed coupling reactions. They are also ideal candidates for the synthesis of Grignard reagents that have wide-applicability in organic synthesis. The reactivity of organobromine compounds resembles but is intermediate between the reactivity of organochlorine and organoiodine compounds. For many applications, organobromides represent a compromise of reactivity and cost.Reference of 83902-02-7

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

Novel Multitarget-Directed Ligands Aiming at Symptoms and Causes of Alzheimer’s Disease was written by Wieckowska, Anna;Wichur, Tomasz;Godyn, Justyna;Bucki, Adam;Marcinkowska, Monika;Siwek, Agata;Wieckowski, Krzysztof;Zareba, Paula;Knez, Damijan;Gluch-Lutwin, Monika;Kazek, Grzegorz;Latacz, Gniewomir;Mika, Kamil;Kolaczkowski, Marcin;Korabecny, Jan;Soukup, Ondrej;Benkova, Marketa;Kiec-Kononowicz, Katarzyna;Gobec, Stanislav;Malawska, Barbara. And the article was included in ACS Chemical Neuroscience in 2018.Reference of 954-81-4 This article mentions the following:

Alzheimer’s disease (AD) is a major public health problem, which is due to its increasing prevalence and lack of effective therapy or diagnostics. The complexity of the AD pathomechanism requires complex treatment, e.g. multifunctional ligands targeting both the causes and symptoms of the disease. Here, we present new multitarget-directed ligands combining pharmacophore fragments that provide a blockade of serotonin 5-HT₆ receptors, acetyl/butyrylcholinesterase inhibition, and amyloid β antiaggregation activity. Compound I has displayed balanced activity as an antagonist of 5-HT₆ receptors (K_i = 18 nM) and noncompetitive inhibitor of cholinesterases (IC_50hAChE = 14 nM, IC_50eqBuChE = 22 nM). In further in vitro studies, compound I has shown amyloid β antiaggregation activity (IC₅₀ = 1.27 μM) and ability to permeate through the blood-brain barrier. The presented findings may provide an excellent starting point for further studies and facilitate efforts to develop new effective anti-AD therapy. In the experiment, the researchers used many compounds, for example, N-(5-Bromopentyl)phthalimide (cas: 954-81-4Reference of 954-81-4).

N-(5-Bromopentyl)phthalimide (cas: 954-81-4) belongs to organobromine compounds. Many of the organo bromine compounds are relatively nonpolar. Bromine is more electronegative than carbon (2.8 vs 2.5) and hence the carbon in a carbon–bromine bond is electrophilic in nature. When the molecular ion is detected, the bromine and chlorine isotope patterns are very distinct, but caution is to be exercised for certain mixed chlorinated/brominated compounds, which can look similar to homohalogen patterns.Reference of 954-81-4

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary